Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172727 | 0.88 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL4597120 | 0.84 | HRH3 (0.37) | — | |
| SCHEMBL9298888 | 0.84 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL4597673 | 0.83 | SLC6A2 (0.39) | GAA | |
| SCHEMBL4595444 | 0.82 | SIGMAR1 (0.46) | — | |
| SCHEMBL4597107 | 0.82 | DRD2 (0.46) | — | |
| SCHEMBL4597224 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL4167404 | 0.80 | CA1 (0.40) | CA1CA2CA9CA12CA4 | |
| SCHEMBL4996530 | 0.80 | CA1 (0.40) | CA1CA2CA9CA12CA4 | |
| SCHEMBL9298111 | 0.78 | CA1 (0.38) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | claimed |
| EP-1842855-A2 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-10 | — | — | EP | claimed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1874788-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-09 | — | — | EP | disclosed |
| EP-1842855-A2 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006111783-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | CA1 2555/4885CA2 4209/4885CA9 1801/4885 |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, MUC1, FUT5 | CA1 2839/4885CA2 4336/4885CA9 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.